| abstract |
The use of a solution comprising epinastine as an active ingredient, optionally in the form of its racemate, enantiomers and optionally in the form of its addition salts with a pharmaceutically acceptable acid, at a concentration of 0.0005 to 0.1% by weight; water or physiological saline solution as a solvent; a pH-adjusting buffer of 6.5 to 7.2, optionally by addition of sodium hydroxide; a preservative; and optionally chelating agents; viscosity modifying agents; penetration enhancers; antioxidants; and / or a physiologically acceptable solution for the solution of the solution, for the manufacture of a medicament for topical application to the conjunctiva or the nasal mucosa, for the treatment of a delayed reaction in an allergic rhinitis or allergic conjunctivitis. |